The mechanisms underlying the Hepatitis C virus (HCV) resistance to interferon alpha (IFN-α) are not fully understood. We used IFN-α resistant HCV replicon cell lines and an infectious HCV cell culture system to elucidate the mechanisms of IFN-α resistance in cell culture. The IFN-α resistance mechanism of the replicon cells were addressed by a complementation study that utilized the full-length plasmid clones of IFN-α receptor 1 (IFNAR1), IFN-α receptor 2 (IFNAR2), Jak1, Tyk2, Stat1, Stat2 and the ISRE- luciferase reporter plasmid. We demonstrated that the expression of the full-length IFNAR1 clone alone restored the defective Jak-Stat signaling as well as Stat1, Stat2 and Stat3 phosphorylation, nuclear translocation and antiviral response against HCV in all IFN-α resistant cell lines (R-15, R-17 and R-24) used in this study. Moreover RT-PCR, Southern blotting and DNA sequence analysis revealed that the cells from both R-15 and R-24 series of IFN-α resistant cells have 58 amino acid deletions in the extracellular sub domain 1 (SD1) of IFNAR1. In addition, cells from the R-17 series have 50 amino acids deletion in the sub domain 4 (SD4) of IFNAR1 protein leading to impaired activation of Tyk2 kinase. Using an infectious HCV cell culture model we show here that viral replication in the infected Huh-7 cells is relatively resistant to exogenous IFN-α. HCV infection itself induces defective Jak-Stat signaling and impairs Stat1 and Stat2 phosphorylation by down regulation of the cell surface expression of IFNAR1 through the endoplasmic reticulum (ER) stress mechanisms. The results of this study suggest that expression of cell surface IFNAR1 is critical for the response of HCV to exogenous IFN-α.
Keywords:Hepatitis C virus (HCV); Interferon alpha (IFN-α); Interferon alpha-receptor 1 (IFNAR1); Jak-Stat signaling; nuclear translocation; reverse transcription polymerase chain reaction (RT-PCR); HCV infection; ER stress
Hepatitis C virus (HCV) is a positive-stranded RNA virus that infects the liver. The majority of patients after initial exposure to the virus develop a chronic infection. Chronic HCV infection can gradually evolve into liver cirrhosis, end stage liver diseases and hepatocellular carcinoma [1-3]. The standard treatment option of chronic HCV infection is the combination of IFN-α and ribavirin . This therapy cures approximately 50% of chronic HCV infections and the HCV in a majority of chronically infected patients develop resistance. The mechanism of IFN-α resistance in these patient populations is not fully understood. Understanding the IFN-α resistance mechanism of HCV infection is important to develop an alternative therapeutic strategy to clear the infection.
To understand the mechanism of HCV resistance to IFN-α, we have utilized stable replicon cell lines and the infectious HCV cell culture model system. The replicon cells express NS3 to NS5B protein required for replication of HCV sub-genomic RNA but they lack structural proteins and do not produce infectious virus. We have isolated nine stable IFN-α resistant Huh-7 based replicon cell lines (HCV1b) after long-term treatment with IFN-α. We have shown that the replication of HCV subgenomic RNA is totally resistant to IFN-α . Each of nine IFN-α resistant Huh-7 replicon cells showed reduced activation of pISRE-firefly luciferase promoter and impaired phosphorylation of Stat proteins [5-7]. All of the cured Huh-7 cell clones showed significant reduction in the ISRE promoter activation and a defect in the Jak-Stat signaling. Previously, we reported that low level expression of Jak1 and Tyk2 kinases in these IFN-α resistant cell lines. However, stable expression of either Jak1 or Tyk2 or both in resistant Huh-7 cells did not complement the defective Jak-Stat signaling and antiviral response of IFN-α.
This current study was performed to elucidate the mechanism of defective Jak-Stat signaling in the IFN-α resistant replicon cell lines as well as infectious HCV cell culture model. The ability of the individual proteins of the Jak-Stat signaling pathway to overcome the reduced IFN-α signaling and ISRE promoter activation in replicon cell culture was examined by complementation. Expression of wild type IFNAR1 protein only complemented the defective Jak-Stat signaling of resistant replicon cell lines. The nuclear translocation of Stat1-GFP, Stat2-GFP, Stat3-GFP and antiviral action of IFN-α was restored in the resistant cells by stable expression of IFNAR1 suggesting the existence of no additional defects in the downstream Jak-Stat pathway. Reverse transcription (RT) PCR and DNA sequence analysis of IFNAR1 mRNA revealed that the defective Jak-Stat signaling and IFN-α resistance was due to the expression of a truncated version of IFNAR1 protein in all resistant Huh-7 cell lines. The truncation in the SD1 and SD4 domains of IFNAR1 blocked the activation of Tyk2 kinase leading to the impaired phosphorylation of downstream Stat1 and Stat2 proteins and defective Jak-Stat signaling. We also reported here that HCV infection directly modulates the expression of IFNAR1 and creates defective Jak-Stat signaling and remains resistant to IFN-α. Results of this in vitro study suggest that altered expression of IFNAR1 leads to defective Jak-Sat signaling and continued resistance to IFN-α in HCV cell culture model.
Materials and methods
Development of IFN-α sensitive and resistant HCV replicon cell lines
Stable resistant replicon cells (HCV1b) were generated in our laboratory by selecting cell clones that survived IFN-α treatment as described previously . Cured IFN-α resistant Huh-7 cells were prepared from an individual resistant replicon cell line by eliminating HCV replication by repeated treatment with cyclosporine-A (1 μg/ml) as described previously . An IFN-α sensitive cured Huh-7 cell line (S-5/15) was prepared from 5-15 replicon cell line by eliminating HCV after IFN-α treatment. Interferon sensitive and interferon resistant phenotypes of cured Huh-7 cells were examined by measuring their ability to activate ISRE-firefly luciferase promoter in the presence of exogenous IFN-α. All HCV positive replicon cell lines were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 2 mM L-glutamine, sodium pyruvate, nonessential amino acids, 100 U/ml of penicillin, 100 mg/ml of streptomycin and 5% fetal bovine serum supplemented with the G-418 (1 mg/ml). The cured Huh-7 cell lines were cultured in the same growth medium without the G-418 drug. A stable cell line expressing IFNAR1 was made by electroporating the cDNA of full length IFNAR1 clone in R-17/3 cells and selecting with DMEM containing G-418 (250 μg/ml). Recombinant human IFN-α 2 b was purchased from Schering Plough (Kenilworth, NJ, USA) and IL-6 was obtained from Peprotech (RockyHill, NJ, USA).
Western blot analysis and antibodies
Antibodies to Jak1, phospho Jak1 (Tyr1022/1023), Tyk2, phospho Tyk2 (Tyr1054/1055), Stat1, phospho Stat1 (Tyr701), Stat2, phospho Stat2 (Tyr690), Stat3, phospho Stat3 (Tyr705), IRE1-α, BiP, PERK, phospho eIF2-α and beta actin were purchased from Cell Signaling (Beverly, MA, USA). The antibody to IFNAR1 and IFNAR2 was obtained from Santa Cruz Biotechnology (Santa Crutz, CA, USA). The monoclonal antibody to HCV core was obtained from Thermo Scientific, Rockford, IL, USA. Western blotting was performed using a standard protocol established in our laboratory. Briefly IFN-α treated or untreated Huh-7 cells cultured in a 6-well plate were lysed with 200 μl of RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) supplemented with protease inhibitors (Thermo Scientific, Rockford, IL, USA) and phosphatase inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany). Total protein in the lysate was quantified using BioRad protein assay kit (BioRad, Hercules, CA, USA). Then equal amount of protein lysates from each sample was mixed in SDS-loading buffers. Proteins were separated by NuPAGE 4-12% gel and then transferred onto a nitrocellulose membrane (GE healthcare, Buckinghamshire, UK). The membrane was blocked with 5% fat-free milk powder in 50 mM TBS pH 7.6 with 0.1% Tween 20 (TBS-Tw20) at room temperature for 1 hour. The membrane was washed three times and incubated overnight at 4°C with a primary antibody diluted in TBS-Tw20 containing 5% fat-free milk powder. After this step, the membrane was washed three times with TBS-Tw20 and reacted for one hour with secondary antibody (either anti-rabbit or anti-mouse supplied in the ECL kit) conjugated with horseradish peroxidase (HRP) at a dilution of 1:2000. Bound antibodies were detected using the ECL Plus Western blotting detection system (GE healthcare, Buckinghamshire, UK) and chemiluminiscent signals were detected using high performance chemiluminescence film (GE healthcare, Buckinghamshire, UK).
The flow analysis of all the nine cured IFN-α resistant cells and cured IFN-α sensitive cells was carried out by using a rabbit monoclonal antibody targeted to the C-terminus of IFNAR1 (Epitomics, Burlingame, CA, USA). The protocol used is as described earlier  with slight modification.
The contribution of each Jak-Stat protein to the mechanisms of IFN-α resistance was examined by complementation studies. The human IFNAR1 and three different IFNAR2 cDNA clones were purchased from OriGene Technologies (Rockville, MD, USA) and from our collaborator . The cDNA clone of human Tyk2 was kindly provided by Sandra Pellegrini, France  and also from the laboratory of John J Krolewski, Columbia University, New York, USA . The full-length cDNA clone of human Jak1 was obtained from the laboratory of Ketty Chou, Roswell Park Cancer Institute, Buffalo, New York, USA . The cDNA clones of human Stat1 and Stat2 GFP were described earlier . Stat3-GFP plasmid was obtained from OriGene Technologies (Rockville, MD, USA). The plasmid pISRE-Luc containing four tandem copies of the 9-27 ISRE positioned directly upstream of the HSV-1TK TATA box, driving the firefly luciferase gene was kindly provided by Steve Goodbourn, St George's Hospital and Medical School, University of London, London, UK . Cured interferon sensitive and resistant Huh-7 cells were plated in 12-well tissue culture dishes. The next day they were transfected with 0.5 μg of ISRE-firefly luciferase plasmid, 0.5 μg of control Renilla luciferase plasmid (pRL-TK) and 1 μg of individual cDNA expression plasmid using the FuGene6 transfection reagent (Roche Diagnostic Corporation, Indianapolis, IN, USA). IFN-α 2 b (1000 IU/ml) was added after the transfection step to examine which Jak-Stat proteins complement the ISRE-mediated activation of the luciferase gene. After 24 hours, cells were treated with a reporter lysis buffer (Promega Madison, WI) according to the manufacturer's instruction. An equal amount of protein extracts (20 μl) was mixed with 100 μl of substrate buffer and luciferase activity was measured by integrating the total light emission over ten second interval in a luminometer (Luman LB9507; EG & G Berthold, Berlin, Germany). The level of luciferase expression in the Huh-7 cells transfected with ISRE promoter was measured with or without IFN-α treatment. The consistency of the results was checked by the repetition of each experiment three times.
Nuclear translocation of Stat-GFP fusion proteins
Cured resistant (R-17/1) and cured sensitive Huh-7 cells (S-5/15) were plated in a two well Lab-Tek chamber slide (Electron Microcopy Sciences, Hatfield, PA, USA) at a density of 5 × 104 cells per ml. Twenty-four hours later, the cells were transfected with 1 μg of the individual STAT-GFP plasmid (Stat1-GFP, Stat2-GFP and Stat3-GFP). At 48 hours post-transfection To-Pro3 nuclear marker (Invitrogen, Molecular Probes, Oregon, USA) was added to the samples at 1 μg/ml and incubated for five minutes in PBS. IFN-α (1000 IU/ml) was then added to the appropriate groups. Confocal microscopy was performed using a Leica TCS SP2 confocal microscope equipped with three lasers (Leica Microsystems, Exton, PA). Optical slices were collected at 512 × 512 pixel resolution. NIH Image version 1.62 and Adobe Photoshop version 7.0 were used to assign correct colors of channels collected, including the Green Fluorescent Protein (green), To-Pro3 633 (far red).
Ribonuclease protection assay (RPA)
Total RNA was isolated from the JFH1-GFP RNA transfected Huh-7 cells by the GITC method and subjected to RPA for HCV positive-strand RNA using an anti-sense RNA probe targeted to the 5' UTR as described previously . The same amounts of the RNA extracts were subjected to RPA for GAPDH mRNA. We used a linearized pTRI-GAPDH-human anti-sense control template to prepare a probe to detect GAPDH mRNA using Sp6 RNA polymerase (Ambion Inc., Austin, TX, USA). The appearance of a 218-nt fragment in the RPA indicated the presence of positive-strand HCV RNA.
RT-PCR and DNA sequencing of full-length IFNAR1
Total RNA was isolated from IFN-α sensitive and resistant cultured Huh-7 cells by the GITC method. The RNA pellet was resuspended in nuclease free water, quantified by a spectrophotometer and stored at -70°C in several aliqouts. Two separate DNA fragments (F1 and F2) covering the full-length IFNAR1 mRNA was amplified from the RNA extracts of cultured Huh-7 cells by RT-PCR (14-16). The first 949 bp fragment (F1) starting from nucleotides 83 to 1032 was amplified using a sense primer (IFNAR1/83/S 5'-ATGGCGGCTGAGAGGAGCTG-3') and antisense primer (IFNAR1/1032/AS 5'-TTGAGGAAAGACACACTGGGTA-3'). The amplified DNA was confirmed by Southern blot analysis using an internal oligonucleotide probe (IFNAR1/Probe/253 5'-GTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGT-3). Likewise, the second 1025 bp fragment (F2) starting from nucleotides 901 to 1926 was amplified using the sense primer (IFNAR1/901/S 5'-TATGCAAACATGACCTTTCAAG-3') and antisense primer (IFNAR1/1926/AS 5'-ACAGGGAAACGTCCTCTCTGTAGTT-3'). The PCR amplified DNA was confirmed by Southern blotting using a probe (IFNAR1 Probe/1633 5'-GAGGAACAAATCGAAAAATGTTTCATAGAAAATATA-3'). The RT-PCR reaction of each fragment was carried out using a standard method established in our laboratory. Briefly, an aliquot of 2 μg of total RNA was incubated with 500 ng of antisense primer and incubated at 65°C for 10 minutes followed by immediate chilling on ice. This template primer mix was subsequently incubated with 10 units of AMV reverse transcriptase (RT) (Promega, Madison, WI, USA), 1.5 mM MgCl2, 1 mM dNTP mix, 40 units RNaseOut (Invitrogen, Carlsbad, CA, USA) in a total of 20 μl reaction volume for 90 minutes at 42°C. Identical reaction without the addition of RT enzyme were used as controls. PCR amplification was carried out using 5 μl of the cDNA products along with 5 unit GoTaq Flexi DNA polymerase in 1X polymerase buffer (Promega, Madison, WI, USA), 200 μM of dNTP mix, 1.5 mM MgCl2, 250 ng of sense and antisense primer in a 50 μl total reaction volume. PCR amplification was carried out for 3 minutes of incubation at 95°C followed by 45 cycles of 30 seconds at 95°C, 30 seconds at 55°C, 1 minute at 72°C, followed by a final 10-minute extension at 72°C. The PCR products were resolved on a 1.5% agarose gel along with 100-bp DNA ladder stained with ethidium bromide, visualized under UV transilluminator and photographed (Fuji Film, Japan). The specificity of the PCR amplified DNA was confirmed by Southern blot analysis using 32P-labeled oligoprobe specific for IFNAR1 sequences (NM_000629) . The PCR products were then run on an agarose gel and purified. DNA sequence analysis was performed at Genewiz Inc, NJ, USA using the sense and antisense primers. The sequences were analyzed using BioEdit Sequence Alignment Editor version 126.96.36.199 software.
IFN-α treatment and the infectious HCV cell culture system
An infectivity assay for HCV was performed using a published protocol . HCV infected Huh-7 cells were treated with an increasing concentration of IFN-α (Intron A, Schering-Plough, NJ, USA). The antiviral effect of IFN-α against HCV was confirmed by observing GFP expression by fluorescence microscopy, Western blot for core and HCV RNA level by real-time RT-PCR and Southern blot analysis. The real-time RT-PCR was done according to our previous publication  and some modifications according to Zhu et al . The southern blot analysis was performed according to Akyol et al .
Defective Jak-Stat signaling in IFN-α resistant replicon cells
To understand the contribution of the virus and host cellular factors in the mechanisms of IFN-α resistance, we first used stable Huh-7 cell lines replicating sub-genomic HCV RNA as a model system. Figure 1 provides an overview of the development of IFN-α resistant replicon Huh-7 cell lines with or without HCV. Nine stable cell lines replicating HCV 1 b replicon RNA were isolated. The role of the viral factors in the mechanism of resistance in replicon cells were excluded because reduced activation of the ISRE promoter was also observed in all cured Huh-7 cell lines, even after eliminating HCV RNA replication by cyclosporine A. These results led us to suspect that altered expression of interferon induced Jak-Stat signaling is the cause of low ISRE promoter activation and IFN-α resistance. To establish the mechanisms of the defective Jak-Stat signaling, the expression levels of Jak-Stat signaling molecules in resistant replicon cell lines were examined in a representative IFN-α sensitive (S-5/15) and an IFN-α resistant cell line (R-17/3) by Western blot analysis using antibodies targeted to the phosphorylated and non-phosphorylated form of Jak1, Tyk2, Stat1 and Stat2 (Figure 2A). It was consistently observed that the phosphorylation of Jak1, Tyk2, Stat1 and Stat2 proteins were completely blocked in R-17/3 cells after IFN-α treatment. Expression levels of total Jak1, Tyk2, Stat1 and Stat2 proteins between the sensitive and resistant Huh-7 cells were not different. Since the expression level of the cell surface receptors (IFNAR1 and IFNAR2) is critical for the IFN-α induced signaling events leading to the phosphorylation of the Jak-Stat proteins, the expression levels of IFNAR1 and IFNAR2 proteins in cured sensitive and resistant Huh-7 cells were measured by Western blot analysis and found to be not significantly different (Figure 2A). The IFNAR1 expression level was also examined using protein lysates prepared from nine different IFN-α resistant Huh-7 cell lines. We detected the ~100-110 kD mature form of IFNAR1 and 90 kD IFNAR2 in all resistant Huh-7 cell lines at levels comparable to those in S-5/15 cells (Figure 2B). The endogenous expression level of IFNAR1 between the cured S-5/15 and cured resistant Huh-7 cell lines was also examined by flow analysis using a monoclonal antibody (Figure 3). Although there were slight variations in the percentage of IFNAR1 positivity between the resistant and sensitive Huh-7 cells by flow analysis, these differences were not significant.
Figure 1. Schematic diagram showing the isolation of IFN-α resistant and sensitive replicon cell lines. Three different HCV 1 b sub-genomic replicon cell lines (Con-15, Con-17 and Con-24) with low ISRE-luciferase activity were cultured in growth media supplemented with G-418 (1 mg/ml) and IFN-α 2 b for more than 4 weeks. Resistant cell colonies that survived the IFN-α 2 b treatment were picked and stable resistant cell lines (R-15, R-17 and R-24 series) were established. Cured Huh-7 cell line from each replicon was prepared by repeated treatment with cyclosporine A (1 μg/ml). All of the cured Huh-7 cells were free from HCV and still maintained low level ISRE-luciferase activity after IFN-α 2 b treatment. 5/15 cell line is IFN-α sensitive HCV 1 b replicon cell line. HCV replication in this cell line was eliminated by IFN-α 2 b and used as the positive control.
Figure 2. Western blot analysis of Jak-Stat signaling between S-5/15 and R-17/3 cell line. An equal number of S-5/15 and R-17/3 Huh-7 cells were treated with IFN-α 2 b (1000 IU/ml). Cells were harvested at different time intervals (in hrs) by trypsin-EDTA treatment, washed in PBS. Western blot analysis was performed using antibodies to IFNAR1, IFNAR2, pJak1, Jak1, pTyk2, Tyk2, pStat1, Stat1, pStat2, Stat2 and β-actin and then blots were developed by ECL kit. (A) Expression level of Jak-Stat proteins between the two cell lines. Left panel shows the expression of Jak-Stat signaling proteins in the IFN-α sensitive Huh-7 cell line (S-5/15). Right panel shows the expression of Jak-Stat signaling proteins in the IFN-α resistant Huh-7 cell line (R-17/3). The level of β-actin protein in the blot indicated that equal amounts of protein lysate were loaded onto the gel in the Western analysis. (B) Show the expression of fully glycosylated mature form of IFNAR1 (~100 kD) and IFNAR2 (~90 kD) in all nine of different IFN-α resistant cell lines and one sensitive Huh-7 cell line (S-5/15) by Western blot analysis.
Figure 3. Flow cytometry of IFNAR1 expression in IFN-α resistant Huh-7 cells. Flow cytomeric analysis demonstrating expression of full-length mature IFNAR1 between the sensitive Huh-7 line (S-5/15) and nine different alpha resistant Huh-7 cell lines using a rabbit monoclonal antibody targeting to the C-terminus of human IFNAR1 at a dilution of 1:50. The secondary antibody used is anti rabbit IgG Alexa Fluor 488 at a dilution of 1:1000 (Invitrogen, Oregon, USA). The % of positive cells was shown for each cell line.
It is known that the type I IFN receptor and the type II IFN receptor consist of two distinct subunits: IFNAR1 and IFNAR1 for type I receptor and IFNGR1 and IFNGR2 for the type II receptor. In the case of the type I IFN receptor, the IFNAR1 subunit is constitutively associated with tyrosine kinase 2 (Tyk2), whereas in the case of the type II IFN receptor, the IFNGR1 subunit is associated with Jak1. The first step in both the type I and Type II IFN-mediated signaling is the activation of these receptor-associated kinases leading to a ligand-dependent rearrangement and dimerization of the receptor subunits followed by autophosphorylation and activation of the receptor associated kinases . To characterize the biochemical interactions that impede the Stat phosphorylation and cellular Jak-Stat signaling in the resistant Huh-7 cells, we examined the phosphorylation of Tyk2 and Jak1 kinases after they were treated with either IFN-α or IFN-γ. We found IFN-α dependent phosphorylation of the Jak1 and Tyk2 and IFN-γ dependent phosphorylation of Jak1 protein in sensitive Huh-7 cells (S-5/15) (Figure 4). When a similar experiment was performed using a resistant cell line R-17/3, we found that only the IFN-α induced phosphorylation of Jak1 and Tyk2 are blocked in these cells (Figure 4). There was no difference in the IFN-γ dependent phosphorylation of Jak1 in the resistant Huh-7 cells. These data suggest that the IFN-α dependent activation of Tyk2 and Jak1 is blocked in the resistant Huh-7 cells (R-17/3) cells.
Figure 4. IFN-α dependent activation of Tyk2 and Jak1 is prevented in resistant Huh-7 cells. Cured S-5/15 and R-17/3 cells were treated with IFN-α 2 b (1000 IU/ml) or IFN-γ (1000 IU/ml) for different time intervals 10, 30 and 60 minutes and cell lysates were examined for Jak1 and Tyk2 phosphorylation by Western blot analysis. Left panel shows the time dependent phosphorylation of Jak1 and Tyk2 kinases in sensitive Huh-7 cells (S-5/15) by IFN-α and IFN- γ (1000 IU/ml). Right panel shows the phosphorylation of Jak1 and not Tyk2 in resistant Huh-7 cells (R-17/3) by IFN-α and IFN-γ (1000 IU/ml). β-actin levels are the same among the protein samples analyzed.
Expression of wild-type IFNAR1 overcomes defective Jak-Stat signaling in resistant Huh-7 cell lines
The role of the individual components of the Jak-Stat signaling proteins in the mechanisms of IFN-α resistance was examined by complementation studies using ISRE-firefly luciferase plasmid and plasmid clones of IFNAR1, IFNAR2a, IFNAR2b, IFNAR2c, Jak1, Tyk2, Stat1 and Stat2. The results of these experiments are summarized in Figure 5A, B and 5C. IFN-α induced ISRE-luciferase activity did not change in R-17/3 Huh-7 cells when it was transfected with individual plasmid cDNA clones for expression of Stat1, Stat2, Jak1 and Tyk2 with or without IFN-α treatment. Interestingly, a significant increase of ISRE-firefly luciferase activity in the cured R-17/3 cells by IFN-α was seen after transfection with full-length cDNA of IFNAR1 (Figure 5A). The induction level of ISRE-luciferase by IFN-α in the R-17/3 cells was comparable to the S-5/15 cells, suggesting that the full-length IFNAR1 was able to rescue the defective Jak-Stat signaling. It is known that there is one isoform of IFNAR1 and three isoforms of IFNAR2 expressed in normal human cells . The contribution of the three different variants of IFNAR2 clones in overcoming the defective Jak-Stat signaling and ISRE promoter activation was examined. Expression of none of the IFNAR2 variants modulated the ISRE-luciferase promoter activity in the R-17/3 cells (Figure 5B). The ability of the IFNAR1 clone alone, complementing the defective Jak-Stat signaling of R-17/3, has prompted us to test whether it can also activate the ISRE promoter in other IFN-α resistant Huh-7 cell lines. Nine different IFN-α resistant cell lines and one sensitive Huh-7 cell line (S-5/15) were co-transfected with IFNAR1 and pISRE-firefly luciferase plasmid. The activation of ISRE-firefly luciferase after IFN-α treatment was measured after 24 hours. In these experiments, the fold induction of the ISRE-luciferase activity in each resistant cell line due to IFN-α treatment was measured. Expression of the IFNAR1 alone overcomes the defective Jak-Stat signaling in all resistant Huh-7 cell clones (Figure 5C).
Figure 5. IFNAR1 protein expression complements the ISRE-firefly luciferase promoter activation in the resistant Huh-7 cells. The cured resistant Huh-7 cell line (R-17/3) was co-transfected with ISRE-firefly luciferase plasmid along with each expression plasmid by FuGene6 transfection reagent. The pRL-TK plasmid was used as a transfection control. After this step, cells were treated with IFN-α (1000 IU/ml). After 24 hours, cells were lyzed and luciferase activity was measured. The graphs represent a relative to control luciferase activity. (A) The activation of ISRE promoter by IFN-α in R-17/3 cells expressing different proteins of Jak-Stat signaling expressed as relative luciferase units (RLU) between IFN-α treated and untreated. Expression of wild type full-length IFNAR1 protein is able to induce the ISRE-Luciferase activity. (B) The induction of ISRE-luciferase activity in the R-17/3 cells by IFN-α in the presence of three different variants of IFNAR2 and wild type IFNAR1 was depicted as fold increase as compared to untreated cells. (C) IFN-α induces the ISRE-Firefly luciferase activity (fold increase) in all nine IFN-α resistant Huh-7 cell lines when they were co-transfected with the wild type IFNAR1 plasmid.
Stable expression of IFNAR1 overcomes impaired phosphorylation, nuclear translocation of Stat and antiviral response to IFN-α
We clarified whether or not stable expression of IFNAR1 in the resistant cells could also improve the down-stream Jak-Stat signaling, and Stat phosphorylation and nuclear translocation. Cured R-17/3 cells were stably transfected with IFNAR1 and selected with G-418 (250 μg/ml). IFN-α induced Stat1 and Stat2 phosphorylation in the resistant Huh-7 cell line (R-17/3), sensitive Huh-7 cell line (S-5/15) and stable IFNAR1 transfected R-17/3 resistant Huh-7 cell line were examined in a kinetic study by Western blotting. Phosphorylation of Stat1, Stat2 and Stat3 proteins were induced by IFN-α treatment only in S-5/15, but not in R-17/3 Huh-7 cells. Stable expression of IFNAR1 in the resistant R-17/3 cell clone restored the phosphorylation of Stat1, Stat2 and Stat3 proteins (Figure 6A). The defective Jak-Stat signaling due to functional inactivation of IFNAR1 did not affect the phosphorylation of Stat1 and Stat3 in the resistant Huh-7 cells after treatment with IL-6 (Figure 6B). However, we noticed there was an increase in the Stat3 phosphorylation by IL-6 in sensitive S-5/15 or in R-17/3 cells with a stable expression of IFNAR1. The impact of restoring the Stat phosphorylation on the nuclear translocation of Stat1, Stat2 and Stat3 protein was examined using chimeric clones of Stat and green fluorescence proteins (Stat1-GFP, Stat2-GFP and Stat3-GFP) in a transient transfection experiment. Results of these experiments suggest that Stat1-GFP, Stat2-GFP and Stat3-GFP proteins efficiently localized to the nucleus of S-5/15 cells after IFN-α treatment (Figure 7). However, Stat1-GFP, Stat2-GFP and Stat3-GFP proteins were localized in the cytoplasm and their nuclear translocation after IFN-α treatment was blocked in the R-17/3 cells. The stable expression of IFNAR1 in the resistant cells corrected the impaired nuclear translocation of Stat1-GFP, Stat2-GFP and Stat3-GFP protein.
Figure 6. Stable expression of IFNAR1 restored the phosphorylation Stat proteins in the cured resistant Huh-7 cell line (R-17/3). The cured Huh-7 cell line (S-5/15) and (R-17/3) in culture were treated either with IFN-α 2 b (1000 IU/ml) or IL6 (50 ng/ml) and cells were harvested after 30 and 60 minutes. Ten micrograms of protein lysate was run on a NuPAGE 4-12% gel and immunoblotting was used to determine pStat1, pStat2 and pStat3 levels. (A) Phosphorylation of Stat1, Stat2 and Stat3 proteins in the sensitive and resistant Huh-7 cells. Left panel shows that IFN-α induced phosphorylation Stat1, Stat2, Stat3 proteins in S-5/15 cells. Middle panel shows the lack of phosphorylation of Stat1 and Stat2 in the R-17/3 cell line after treatment with IFN-α. Right panel shows that the stable transfection of R-17/3 cells with IFNAR1 restores the Stat1 and Stat2 phosphorylation by IFN-α treatment. Total Stat1 and Stat2 levels were indistinguishable. (B) Shows that IL-6 induced phosphorylation of Stat1 and Stat3 in Jak-Stat sensitive and defective Huh-7 cells.
Figure 7. Confocal microscopy showing the nuclear translocation of Stat1, Stat2 and Stat3-GFP in sensitive and resistant Huh-7 cells after IFN-α treatment. IFN-sensitive (S-5/15) and IFN-resistant (R-17/3)) cells were transfected with plasmid containing the Stat1-GFP, Stat2-GFP or Stat3-GFP. IFN-α 2 b (1000 IU/ml) was added after 48-hours of transfection and images were captured after 30 minutes of treatment. The nuclear translocation of each STAT-GFP construct with or without IFN-α treatment in the sensitive and resistant cells was examined under a confocal microscope. The images are represented as the superimposition of Green Fluorescent Protein (green), To-Pro3 633 (far red).
We also examined whether the stable expression of IFNAR1 in the resistant cells could improve the antiviral action of IFN-α against HCV replication. Three different cured Huh-7 cells were transfected with in vitro transcribed full-length HCV-GFP RNA (JFH1-GFP) by the electroporation method described previously . After 24 hours, transfected cells were cultured in a medium containing IFN-α (1000 IU/ml). Positive strand HCV-RNA levels in the transfected Huh-7 cells were measured by RPA assay after 72 hours. The presence of 218 nucleotide protected fragment in all three Huh-7 cells lines suggested that replication of full-length HCV-GFP RNA has occurred in all three Huh-7 cell lines at 72 hours after transfection. The results of RPA assay indicate that stable expression of the IFNAR1 in the resistant Huh-7 cells made HCV replication sensitive to IFN-α (Figure 8A). The antiviral effect of IFN-α against full-length HCV RNA replication was also measured by comparing cytoplasmic HCV-GFP expression in Huh-7 cells with and without IFN-α treatment after 72 hours. IFN-α effectively inhibits HCV replication in sensitive S-5/15 but not in R-17/3 cells (Figure 8B). HCV-GFP expression was inhibited in R-17/3 cells after stable expression of IFNAR1. IFN-α only inhibits HCV RNA replication in the S-5/15 cell line and R-17/3 cell line stable expressing IFNAR1. HCV RNA replication is not inhibited in R-17/3 cells with the defective IFNAR1 expression.
Figure 8. Stable expression of IFNAR1 improves the antiviral response of IFN-α in resistant R-17/3 cells. Cured Huh-7 cells prepared from S-5/15 and R-17/3 cells were transfected with full-length JFH1-GFP chimeric HCV RNA by electroporation. After 72 hours, these cells were treated with IFN-α (1000 IU/ml) for an additional 72 hours. Replication of HCV in the transfected cells was examined by GFP expression and positive-strand HCV-RNA was detected by RPA using a probe targeted to the highly conserved 5'UTR. (A) HCV RNA levels before and after IFN-α treatment was measured by RPA. Left panel shows that high level HCV RNA replication in different Huh-7 clones without IFN-α treatment. Right panel shows the HCV RNA level in the same set of Huh-7 cell lines after IFN-α treatment. IFN-α inhibits the level of HCV RNA in IFN-α sensitive Huh-7 cells, but not in the resistant Huh-7 cell line. The antiviral effect of IFN-α can be restored upon stable expression of IFNAR1 in the resistant Huh-7 cell line. The GAPDH mRNA levels served as controls. (B) Expression and replication of HCV-GFP in the transfected Huh-7 cells before and after IFN-α treatment was measured by fluorescence microscopy at 20X magnification. The upper panel shows the expression HCV-GFP chimera protein in different Huh-7 cell lines transfected with HCV without IFN-α treatment. The lower panel shows the expression HCV-GFP in the same set of Huh-7 cells after IFN-α treatment. Positive expression indicates the impaired antiviral effect of IFN-α against HCV.
All resistant Huh-7 cell lines show expression of truncated IFNAR1
Total RNA was isolated from sensitive (S-5/15) and three resistant (R-15/1, R-17/1 and R-24/1) Huh-7 cell clones and the mRNA level of IFNAR1 was examined by real-time RT-PCR. No differences were observed in the level of mRNA using the primer sets targeted to the N-terminal region of IFNAR1 (data not shown). We then used RT-PCR based assay to amplify the full-length mRNA of IFNAR1 in all resistant Huh-7 cell lines (Figure 9A). The full-length IFNAR1 in each resistant Huh-7 cell lines was amplified into two fragments (F1 and F2) using four sets of overlapping primers (Figure 9A). The RT-PCR amplified DNA was confirmed by Southern blotting (data not shown). The sequence of PCR amplified full-length IFNAR1 between sensitive (S-5/15) and nine different resistant Huh-7 cell lines analyzed by using web-based computer software (BioEdit Sequence Alignment Editor Version 188.8.131.52). The DNA sequence comparison of IFNAR1 mRNA between the S-5/15 cell line and one resistant Huh-7 cell clone of R-15, R-17 and R-24 series (Figure 9B). This suggested that 5'truncation of IFNAR1 protein in R-15 and R-24 series compared to 3'truncation of extracellular domain of IFNAR1 in R-17/3 cells. IFNAR1 (557 aa) consists of an extracellular domain (436 amino acids), a hydrophobic transmembrane domain of 21 amino acids and a C-terminal intracytoplasmic domain of 100 amino acids [17-19]. The extracellular domain of IFNAR1 consists of four Ig-like sub-domains (SDs) essential for ligand binding and receptor assembly on the cell surface. The R-15 and R-24 series IFN-α resistant replicon cell lines have a deletion of 58 amino acids (68-125 aa), (SD1 domain) while the R-17 series resistant replicon line showed deletion of 50 amino acids (382-431aa) (SD4 domain).
Figure 9. Schematic diagram and sequence analysis of open reading frame of human IFNAR1 by RT-PCR from the S-5/15 and R-15/1, R-17/1 and R-24/1 cells. (A) Location of sense and antisense primers used for RT-PCR analysis of IFNAR1 coding sequence. The human IFNAR1 protein is 557 amino acids long that consist of an N-terminal extracellular cytokine-binding (EC) domain (436 aa), a hydrophobic transmembrane (TM) domain (21 aa), and C-terminal intracytoplasmic (IC) domain (100 aa). F1 and F2 are the two PCR fragments amplified for final overlapping PCR of full-length IFNAR1. (B) The amino acid sequence of IFNAR1 of S-5/15 cells perfectly matches with the reference wild type sequence of IFNAR1 m RNA (Accession no- NM_000629). The R-15 and R-24 series resistant Huh-7 clone show an N-terminal deletion of 58 amino acids starting from 68 aa to 125 aa in the IFNAR1. The R-17 series resistant Huh-7 cell clones show deletion of 50 amino acids staring from 382aa to 431 aa in the SD4 domain of IFNAR1. The dotted line indicates the deletion portion in the sequence.
HCV replication in the infected cell culture is resistant to IFN-α
Additional experiments were performed to rule out the possibilities that the resistant phenotype of the replicon cells could be due to an artifact of dual selection of IFN and G418. The findings of HCV resistance to IFN in replicon cell culture was confirmed by using more relevant model of persistently infected full-length HCV in cell culture. Cured S-5/15 cells were infected with a HCV JFH1-GFP chimera virus as described earlier . After 96 hours, infected cells were treated with different concentrations of IFN-α (10-1000 IU/ml) for 72 hours. Results shown in Figure 10A indicate that GFP expression was not completely inhibited after IFN-α treatment. Western blot analysis of HCV core protein confirmed the incomplete antiviral response of IFN-α treatment (Figure 10B). The intracellular HCV RNA content in the infected cell culture after IFN-α treatment was also measured by a real-time RT-PCR assay (Figure 10C) indicating that the levels of HCV RNA did not decrease in a dose dependent manner. The levels of HCV in the infected cell culture receiving continuous IFN-α treatment over two passages were examined by more sensitive assays like RT-nested PCR followed by Southern blot analysis (Figure 10D). No significant change in the intensity of Southern blot signal between the untreated and treated samples was observed, thus confirming that HCV replication in the infected cell culture is not inhibited completely by IFN-α.
Figure 10. HCV replication in the infected cell culture is resistant to IFN-α. Huh-7 cells were treated with different doses IFN-α 2 b (1000 IU/ml)96 hrs after HCV infection. (A) After 72 hours of treatment HCV levels in the infected cells were examined for HCV-GFP expression under a fluorescence microscope. (B) HCV core protein detection by Western blot analysis and β-actin as loading control. (C) HCV mRNA detection by real-time RT-PCR after IFN-α 2 b treatment with different doses. The HCV mRNA was expressed as log copies per μg of cellular RNA. The dotted line indicates the detection limit of the assay. (D) HCV RNA detection in the multicycle infected cell culture by RT-nested PCR (RT-N PCR) and Southern blot (SB) analysis. The P1/T1 and P2/T2 represents the number of passage of HCV infection and treatment.
HCV infection down regulates IFNAR1 expression and Jak-Stat signaling
To understand the mechanism by which HCV replication in the infected cells develop resistance to IFN-α, the expression level of IFNAR1 in cured S-5/15 Huh-7 cells was examined by Western blot and flow analysis over time after HCV JFH1-GFP infection. Protein lysates of HCV infected cells were examined for IFNAR1 levels by Western blot analysis. Expression of functional IFNAR1 (~100-110 kD) is down regulated after HCV infection over time (Figure 11A). The decrease in the IFNAR1 level correlates well with the increase in the HCV core protein expression in the same lysates, whereas the beta actin level remained unaltered. The result of these Western blot analyses were also verified by flow cytometric analysis using a rabbit monoclonal antibody that detects the surface expression of IFNAR1 (Figure 11B). There was a significant decrease in the cell surface expression of IFNAR1 (92% to 5%) over a 10-day period in the HCV infected cured S-5/15 cells. These results confirm that HCV infection itself down regulates the cell surface expression of IFNAR1. The down-regulated expression of IFNAR1 in the infected cells impaired the phosphorylation of Stat1 and Stat2 proteins measured by Western blot analysis (Figure 11C). Using IFN-β promoter luciferase reporter plasmid, we observed that HCV infection showed a time dependent reduction of ISRE-luciferase promoter activity (Figure 11D). A previous study by Liu et al  reported that full-length HCV replication created an unfolded protein response (UPR), that downregulates the expression of IFNAR1. Therefore, the ER stress responses of HCV JFH1-GFP replication in the cured S-5/15 cells were measured by Western blot analysis. An increase in IRE1α, BiP, PERK and phospho eIF2-α levels in the HCV infected Huh-7 cells is clearly observed (Figure 11E). These results are in agreement with the fact that HCV infection itself triggers ER stress response and down regulate the expression of IFNAR1. These results now partially account for the mechanisms by which HCV replication in the infected cell culture is resistant to IFN-α.
Figure 11. HCV infection down-regulate IFNAR1 and induces defective Jak-Stat signaling through ER-stress mechanisms. (A) Cured S-5/15 Huh-7 cells were infected with cell culture derived HCV. Infected and uninfected cells were collected at different time points (0 to 96 hrs) and examined for mature form of IFNAR1 protein by Western blot analysis. (B) The cellular expression of IFNAR1 in the uninfected and infected Huh-7 cells was examined by Flow analysis at different time (0 to 240 hrs). The percentage of positive cells at each time point indicates the cells having the IFNAR1 expression. The peak shifts with time. (C) The phosphorylation of Stat1 and Stat2 protein in the HCV transfected Huh-7 cells was examined by Western blot analysis. The cells were treated with IFN-α for 30 minutes prior to lysis for detection of phosphoproteins. The beta actin in all the blots was used as loading control. (D) Jak-Stat signaling of HCV transfected Huh-7 cells was examined at different time points using a Firefly Luciferase activity of interferon-beta promoter. (E) HCV replicating Huh-7 cells were collected at different time intervals (0 to 96 hrs), protein extracts were examined for the activation of ER-stress response using panel of monoclonal and polyclonal antibodies to IRE1-α, Bip, PERK and phospho EIF2-α. Beta actin level were measured to assure, that equal amounts of proteins were loaded onto the SDS-PAGE gel are used in the Western blotting.
The standard treatment for chronic HCV infection is IFN-α and ribavirin. The majority of patients do not respond to this treatment. The molecular mechanisms as to why certain groups of chronic HCV patients respond well to this treatment while others do not are unclear. The low response rate to IFN-α has been ascribed to a combination effect of viral and host related factors [21,22]. To understand the viral and host cellular factor contributing to IFN-α resistance, we have developed stable replicon cell lines that are sensitive and resistant to IFN-α. In the replicon based cell culture model, the viral protein NS3 to NS5B does not appear to be responsible for blocking the IFN-α antiviral response. Each of nine IFN-α resistant Huh-7 cell lines have defective Jak-Stat signaling even after eliminating HCV sub-genomic RNA. Phosphorylation of Jak1, Tyk2, Stat1, Stat2 and Stat3 protein was blocked in resistant Huh-7 cell lines, but not in the sensitive Huh-7 cells. The impaired phosphorylation of Jak1, Tyk2 and Stat proteins in the resistant Huh-7 cells are not caused by a low-level expression IFNAR1 or degradation of IFNAR1 since a fairly high-level expression of IFNAR1 and IFNAR2 protein were detectable by Western blot and flow analysis. In a previous study, we reported that R-Con-15, R-Con-17 and R-Con-24 series cells have substantially reduced the expression level of Tyk2 and Jak1 levels (5). Using complementation experiments we found that over-expression of Jak1 and Tyk2 in these resistant cell lines did not improve the ISRE-luciferase activity and Jak-Stat signaling. These results suggest that the reduced expression of Jak1 and Tyk2 kinases is not the only cause of defective Jak-Stat signaling. Therefore, the roles of other IFN-α signaling proteins in the mechanism of defective Jak-Stat signaling were further investigated. Through complementation experiments, we learned that expression of wild type IFNAR1 alone in the resistant Huh-7 cells overcame defective Jak-Stat signaling in all IFN-α resistant cells lines. The defective Jak-Stat signaling and IFN-α resistance is related to the defective nature of IFNAR1 protein. Stable expression of IFNAR1 overcame the down stream Jak-Stat signaling as well as the antiviral response against HCV in cell culture. The defective expression of IFNAR1 in the resistant Huh-7 cells was confirmed by DNA sequence analysis. Based on these results, we propose a model (Figure 12) that explains how the amino acid deletions in the extracellular sub-domains of IFNAR1 protein results in alteration of receptor-ligand interactions and subsequent inactivation of tyrosine kinases (Jak1 and Tyk2). This event will affect the phosphorylation of Stat proteins leading to the creation of defective down-stream Jak-Stat signaling in resistant replicon cell lines. Dysregulation of Stat3 signaling has been linked to cancer development . There is evidence suggesting a high incidence of hepatocellular carcinoma in chronically infected HCV patients that are non-responders to interferon therapy [24,25]. The results of our study revealed that Stat3 phosphorylation and nuclear translocation are also blocked in the IFN-α resistant replicon cell line. We also noticed that the IL-6 mediated Stat3 phosphorylation is stronger in cells stably expressing IFNAR1. The significance of Stat3 phosphorylation by IFN-α and IL-6 should be investigated further because the deregulated Stat3 signaling has been linked to a number of cellular events including cellular differentiation, proliferation and survival as well as immune function. The impaired Stat3 phosphorylation and nuclear translocation in the Huh-7 cells with defective Jak-Stat signaling may be an important cellular event in the pathogenesis of chronic HCV infection. The replicon based cell culture experiments established that the truncation in the SD1 and SD4 region of the IFNAR1 protein prevented its association with receptor associated Tyk2 kinase leading to the impaired Stat1 and Stat2 phosphorylation and interferon stimulating gene (ISG) expression that resulted in the impaired antiviral state in the resistant Huh-7 cell culture.
Figure 12. Schematic diagram summarizing the amino acid deletion of extracellular domain of IFNAR1 protein found in the IFN-α resistant Huh-7 cells. Left panel: Four extracellular domains of IFNAR1 in the sensitive cell line with no deletion. Middle panel: 58 amino acid deletions in the SD1 domain in the R-15 and R-24 series clones. Right panel: 50 amino acid deletions in the SD-4 domain of the R-17 series clones. The three series of cell lines demonstrate different variants of IFNAR1 and how the signaling is blocked due to the deletion of extracellular domains of IFNAR1.
Since we could not find any evidence for the contribution of viral factors in the mechanisms of IFN-α resistance in the replicon based cell culture, the interferon resistance mechanism was further examined using a transfected and/or infected full-length HCV cell culture model. We found that HCV infected cells are relatively resistant to IFN-α. The replication of HCV in the infected Huh-7 cells was not inhibited even after using a high dose of IFN-α. This is consistent with the fact as described in many clinical studies, IFN-monotherapy has been reported to be largely ineffective [26,27]. Here we showed that HCV infection directly modulated the IFNAR1 expression and induced defective Jak-Stat signaling in the cell culture model. We provide evidence that the resistant mechanism of the infectious cell culture also targets the cell surface expression of IFNAR1. Our findings are in agreement with a report of Liu et al  who demonstarted that HCV induced UPR and down regulates the cell surface expression of IFNAR1 in PERK-dependent manner. The mechanisms of down regulation of IFNAR1 in the HCV replicating cells were suggested to be due to the phosphorylation-dependent ubiquitination and degradation of IFNAR1.
The contribution of IFNAR1 expression in the development of defective Jak-Stat signaling and IFN-α resistance is now supported by our study along with studies conducted in the laboratory of Nabuyuki Kato . These investigators have also isolated IFN-α resistant Huh-7 based replicon cell lines and demonstrated that cellular factors, particularly functional inactivation of IFNAR1 rather than viral factors contributed to a highly IFN-α resistant phenotype. The authors found nonsense mutations and deletions in type I IFN receptor genes (IFNAR1 and IFNAR2c) in replicon cells showing a highly IFN-α/β resistant phenotype. A number of clinical studies have also been published during recent years where the role of IFNAR1 expression has been correlated with the response to IFN-α therapy in chronic hepatitis C. The studies conducted by Taniguchi et al.,  indicated that high intrahepatic mRNA levels of IFNAR1 and the ratio of IFNAR1 to IFNAR2 were significantly higher in patients having a sustained viral response (SVR) to IFN-α therapy. Another study by Katsumi et al.,  investigated whether the IFN receptor gene expression (IFNAR1 and IFNAR2 mRNA) in the liver could predict the long-term response to therapy in patients with genotype 2a and 2b HCV infection. These investigators found that the expression rate of IFNAR1 and IFNAR2 were significantly higher in responders than non-responders. Fujiwara et al  have conducted a study where the expression of IFNAR1 receptor and response to interferon therapy was examined in chronic hepatitis C patients. They found that the IFNAR2 expression level in the liver not in the PBMC is predictive of the response to IFN-α treatment in chronic hepatitis C patients. A study by Meng et al.,  also examined the expression of IFN-α and β receptor in the liver of patients with a hepatitis C virus related chronic liver disease between patients with IFN responders and nonresponders. In this study, the authors found that the expression of the interferon receptor was more obvious in the IFN-α treatment responsive group than in the non-responsive group. Welzel et al.,  have analyzed the relationship between variants in the IFN-α pathway and SVR among participants in the hepatitis C antiviral long-term treatment against the cirrhosis (HALT-C) trial. They found statistical significance in the IFNAR1 expression and that the IFNAR2 expression is associated with a response to antiviral therapy of chronic HCV patients. These studies, along with our own, have now provided evidence regarding the role of IFN-α induced Jak-Stat pathway contribution to the acquisition of IFN-α resistance in chronic hepatitis C. The replicon based cell culture model used here lacks the structural genes of HCV. Using the HCV JFH1-GFP full-length infectious cell culture model, we have found that cells having full-length HCV replication also develop defective Jak-Stat signaling by downregulating cell surface expression of the IFNAR1. In summary, these results of HCV cell culture studies using Huh-7 cells suggests that defective expression of IFNAR1 of the Jak-Stat signaling of interferon could lead to the development of HCV resistance to IFN-α treatment. The significance of the results of this cell culture study needs to be validated in chronically HCV infected liver disease patients who are non-responders to IFN-α and to understand the importance of Jak-Stat signaling in the cellular response to IFN treatment.
The authors declare that they have no competing interests.
SND, SH, PKC contributed equally and performed all the biochemical experiments, participated in the design and analysis of the data and writing of the manuscript. MS, BP and FG contributed to western blot and luciferase assay experiments. WCW performed the structural analysis of the IFNAR1. HH, MK and CL provided some of the constructs used in this study. LB and RFG critically edited the manuscript. SD provided overall supervision of the study design, data analysis and writing of the manuscript. All authors read and approved the final manuscript.
We thank Mallory Heath for critically reading the manuscript. The authors thank Ralf Bartenschlager for providing the 5/15, 9/13 replicon cell line, Takaji Wakita for providing the JFH1 2a and pSGR clone. The authors thank Sandra Pellegrini for Tyk2 cDNA clone, John J Krolewski, Columbia University, and Ketty Chou, Roswell Park Cancer Institute, Buffalo, New York for human Jak1 and Tyk2 cDNA clones, Steve Goodbourn, St George's Hospital and Medical School, University of London, London, UK for pISRE-Luc plasmid and HSV-1TK-firefly luciferase plasmids. This research project was significantly delayed due to Hurricane Katrina, 2005. We were able to recover these losses due to supplemental funding from the NCI and Gayer Foundation, New York. This work was supported from NIH grant CA127481 and CA129776 and funds received from Louisiana Cancer Research Consortium (LCRC).
Semin Liv Dis 2005, 25:7-17. Publisher Full Text
Hazari S, Chandra PK, Poat B, Datta S, Garry RF, Foster TP, Kousoulas G, Wakita T, Dash S: Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway.
Pai M, Prabhu R, Panebra A, Nangle S, Haque S, Bastian F, Garry RF, Agrawal K, goodbourn S, Dash S: Activation of interferon stimulated response element in a Huh-7 cell line replicating hepatitis C virus sub-genomic RNA.
Claudinon J, Gonnord P, Beslard E, Marchetti M, Mitchell K, Boularan C, Johannes L, Eid P, Lamaze C: Palmitoylation of interferon-alpha (IFN-α) receptor subunit IFNAR1 is required for the activation of Stat1 and Stat2 by IFN-alpha.
Cajean-Feroldi C, Nosal F, Nardeux PC, Gallet X, Guymarho J, Baychelier F, Sempe P, Tovey MG, Escary JL, Eid P: Identification of residues of the IFNAR1 chain of the type I human interferon receptor is critical for ligand binding and biological activity.
Mod Pathol 1992, 5:501-504. PubMed Abstract
Liu J, HuangFu WC, Suresh Kumar KG, Qian J, Casey JP, Hamanka RB, Grigoriadou C, Aldabe R, Diehl JA, Fuchs SY: Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor.
Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, Di Bisceglie AM, Tavis JE, Virahep-C Study Group: Contribution of genome-wide HCV genetic differences to outcome of interferon based therapy in Caucasian American and African American Patients.
Imai Y, Tamura S, Tanaka H, Hiramastu N, Kiso S, Doi Y, Inada M, Nagase T, Kitada T, Imanaka K, Fukuda K, Takehara T, Kasahara A, Hayashi N: Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushijin T, Kurashige N, Inoue Y, Igura T, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Yoshihara H, Inoue A, Imai Y, Kato M, Kiso S, Kanto T, Takehara T, Kasahara A, Hayashi N: Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis.
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alpha-2b alone or combinantion with ribavirin as initial treatment for chronic hepatitis C.
Naka K, Takemoto K, Abe K, Dansako H, Ikeda M, Shimotohno K, Kato N: Interferon resistance of hepatitis C virus replicon-harbouring cells is caused by functional disruption of type 1-interferon receptors.
Taniguchi H, Iwasaki Y, Takahashi A, Shimomura H, Moriya A, Yu PC, Umeoka F, Fujioka S, Koide N, Shiratori Y: Intrahepatic mRNA levels of type I interferon receptor and interferon stimulated genes in genotype 1b chronic hepatitis C.
Katsumi M, Katsuaki T, Satoru S, Takehiko K, Masaaki K: Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection.
Fujiwara D, Hino K, Yamaguchi Y, Kubo Y, Yamashita S, Uchida K, Konishi T, Nakamura H, Korenaga M, Okuda M, Okita K: Type 1 interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study.
Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR, HALT-C Trial Group: Variants in Interferon-alpha pathway genes and response to pegylated interferon-alpha 2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C Antiviral Long-term treatment against Cirrhosis trial.